1
|
Husni ME, Mease PJ, Merola JF, Tillett W, Goldammer N, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies. RMD Open 2024; 10:e004464. [PMID: 39313302 PMCID: PMC11418537 DOI: 10.1136/rmdopen-2024-004464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2024] [Accepted: 07/25/2024] [Indexed: 09/25/2024] Open
Abstract
OBJECTIVES To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies. METHODS BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug (bDMARD)-naïve) and BE COMPLETE (NCT03896581; tumour necrosis factor inhibitor inadequate response/intolerance (TNFi-IR)) are phase 3 studies of subcutaneous bimekizumab 160 mg Q4W; both were double-blind and placebo-controlled to 16 weeks. Patients were randomised 3:2:1 to bimekizumab, placebo or reference (subcutaneous adalimumab 40 mg Q2W) in BE OPTIMAL; 2:1 to bimekizumab or placebo in BE COMPLETE. Patient-reported outcomes for pain, fatigue, physical function and HRQoL are reported to week 16 using pooled and individual study data for bimekizumab and placebo patients. RESULTS 1073/1112 (96.5%) patients completed week 16 (bimekizumab: 677/698 [97.0%]; placebo: 396/414 [95.7%]). Bimekizumab-treated patients achieved rapid improvements vs placebo in pain, fatigue, physical function and HRQoL by week 4, after a single dose. Improvements continued to week 16 for all patient-reported outcomes, including Pain Visual Analogue Scale (VAS; mean (95% CI) change from baseline: bimekizumab: -25.2 [-27.2, -23.1]; placebo: -5.7 [-8.2, -3.3]) and FACIT-Fatigue (bimekizumab: 4.5 [3.9, 5.1]; placebo: 1.1 [0.3, 2.0]); both nominal p<0.001. Greater proportions of bimekizumab-treated patients achieved minimal clinically important differences for patient-reported symptoms vs placebo, including FACIT-Fatigue (bimekizumab: 53.1%; placebo: 36.3%) and HAQ-DI (bimekizumab: 53.0%; placebo: 28.7%); both nominal p<0.001. CONCLUSION Bimekizumab treatment demonstrated rapid and greater improvements in patient-reported pain, fatigue, physical function and HRQoL to week 16 vs placebo in bDMARD-naïve and TNFi-IR patients. TRIAL REGISTRATION NUMBER ClinicalTrials.gov: NCT03895203; NCT03896581.
Collapse
Affiliation(s)
- M Elaine Husni
- Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA
- Orthopedic and Rheumatologic Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
| | - Philip J Mease
- Swedish Medical Center and Providence St. Joseph Health/University of Washington, Seattle, Washington, USA
| | - Joseph F Merola
- Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Division of Rheumatology, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - William Tillett
- Royal National Hospital for Rheumatic Diseases, Bath, UK
- Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK
| | | | | | | | | | | | - Dafna D Gladman
- Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
2
|
Gossec L, Orbai AM, de Wit M, Coates LC, Ogdie A, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology (Oxford) 2024; 63:2399-2410. [PMID: 38754125 PMCID: PMC11371372 DOI: 10.1093/rheumatology/keae277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 04/25/2024] [Accepted: 05/10/2024] [Indexed: 05/18/2024] Open
Abstract
OBJECTIVES To evaluate 1-year bimekizumab efficacy in PsA from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire. METHODS BE OPTIMAL (NCT03895203; biologic DMARD [bDMARD]-naïve), BE COMPLETE (NCT03896581; inadequate response/intolerance to TNF inhibitors [TNFi-IR]) and BE VITAL (NCT04009499; open-label extension) assessed bimekizumab 160 mg every 4 weeks in patients with PsA. Post hoc analyses of patient-reported disease impact, assessed by the PsAID-12 questionnaire, are reported to 1 year (collected to Week 40 in BE COMPLETE). RESULTS Overall, 1,112 total patients were included (698 bimekizumab, 414 placebo). Rapid improvements observed with bimekizumab treatment at Week 4 continued to Week 16 and were sustained to 1 year. At 1 year, mean (SE) change from baseline in PsAID-12 total score was comparable between bimekizumab-randomized patients and patients who switched to bimekizumab at Week 16 (bDMARD-naïve bimekizumab -2.3 [0.1], placebo/bimekizumab -2.2 [0.1]; TNFi-IR bimekizumab -2.5 [0.1], placebo/bimekizumab -2.2 [0.2]). Proportions of bimekizumab-randomized patients achieving clinically meaningful within-patient improvement (≥3-point decrease from baseline) at Week 16 were sustained to 1 year (bDMARD-naïve 49.0%; TNFi-IR 48.5%) and were similar for placebo/bimekizumab patients (bDMARD-naïve 44.4%; TNFi-IR 40.6%). Across studies and arms, 35.3% to 47.8% of patients had minimal or no symptom impact at 1 year. Improvements were observed to 1 year across all single-item domains, including pain, fatigue and skin problems. CONCLUSION Bimekizumab treatment resulted in rapid and sustained clinically meaningful improvements in disease impact up to 1 year in bDMARD-naïve and TNFi-IR patients with PsA. TRIAL REGISTRATION BE OPTIMAL: NCT03895203; BE COMPLETE: NCT03896581; BE VITAL: NCT04009499 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Laure Gossec
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
- AP-HP, Pitié Salpêtrière Hospital, Rheumatology Department, Paris, France
| | - Ana-Maria Orbai
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Maarten de Wit
- Patient Research Partner, Stichting Tools, Amsterdam, The Netherlands
| | - Laura C Coates
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK
| | - Alexis Ogdie
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | | | - Dafna D Gladman
- Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, ON, Canada
| |
Collapse
|
3
|
Ng BCK, Jadon D, Adebajo A, Ayan G, Duffin KC, Chandran V, Coates LC, D'Agostino MA, de Vlam K, Deodhar A, Eder L, Garg A, Gladman DD, Goel N, Gottlieb AB, Husni ME, Katz A, Kavanaugh A, Lubrano E, Mease PJ, Merola JF, Nash P, Ogdie A, Pennington SR, Perez-Chada LM, Proft F, Rosen CF, Savage L, Goldenstein-Schainberg C, Siebert S, Soriano ER, Steinkoenig I, Tillett W, Armstrong AW, FitzGerald O. Proceedings of the GRAPPA 2022 Executive Retreat. J Rheumatol 2023; 50:71-77. [PMID: 37527861 DOI: 10.3899/jrheum.2023-0537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/30/2023] [Indexed: 08/03/2023]
Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) leadership congregated for a strategic planning meeting before the 2022 GRAPPA annual meeting in New York, USA. Meeting aims were to review GRAPPA's performance in relation to its 2016 goals and identify successes and areas for further improvement, identify key GRAPPA priorities and activities for the next 5 years, and explore committee structures to best support these aims.
Collapse
Affiliation(s)
- Beverly Cheok Kuan Ng
- B.C.K. Ng, MBBS, MSc, D. Jadon, MBBCh, PhD, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, UK
| | - Deepak Jadon
- B.C.K. Ng, MBBS, MSc, D. Jadon, MBBCh, PhD, Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, UK
| | - Adewale Adebajo
- A. Adebajo, MD, MBE, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK
| | - Gizem Ayan
- G. Ayan, MD, Division of Rheumatology, Department of Internal Medicine, Hacettepe University Medical Faculty, Ankara, Turkey
| | - Kristina Callis Duffin
- K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
| | - Vinod Chandran
- V. Chandran, MD, DM, PhD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada
| | - Laura C Coates
- L.C. Coates, MD, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | | | - Kurt de Vlam
- K. de Vlam, MD, PhD, University Hospitals Leuven, Leuven, Belgium
| | - Atul Deodhar
- A. Deodhar, MD, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA
| | - Lihi Eder
- L. Eder, MD, PhD, Women's College Research Institute and University of Toronto, Toronto, Ontario, Canada
| | - Amit Garg
- A. Garg, MD, Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, Hempstead, New York, USA
| | - Dafna D Gladman
- D.D. Gladman, MD, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada
| | - Niti Goel
- N. Goel, MD, Patient Research Partner, Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
| | - Alice B Gottlieb
- A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - M Elaine Husni
- M.E. Husni, MD, MPH, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA
| | - Arnon Katz
- A. Katz, MSc, Technion Israel Institute of Technology, Haifa, Israel
| | - Arthur Kavanaugh
- A. Kavanaugh, MD, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, California, USA
| | - Ennio Lubrano
- E. Lubrano, MD, PhD, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
| | - Philip J Mease
- P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, Washington, USA
| | - Joseph F Merola
- J.F. Merola, MD, MMSc, Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Peter Nash
- P. Nash, MBBS, MD, School of Medicine, Griffith University, Brisbane, Australia
| | - Alexis Ogdie
- A. Ogdie, MD, MSCE, Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
| | - Stephen R Pennington
- S.R. Pennington, PhD, O. FitzGerald, MBBCh, MD, School of Medicine, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
| | - Lourdes M Perez-Chada
- L.M. Perez-Chada, MD, MMSc, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Fabian Proft
- F. Proft, MD, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Cheryl F Rosen
- C.F. Rosen, MD, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Laura Savage
- L. Savage, MBChB, PhD, Department of Dermatology, University of Leeds, Leeds, UK
| | - Claudia Goldenstein-Schainberg
- C. Goldenstein-Schainberg, MD, PhD, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Stefan Siebert
- S. Siebert, MD, School of Infection and Immunity, University of Glasgow, Glasgow, UK
| | - Enrique R Soriano
- E.R. Soriano, MD, MS, University Institute and Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | | | - William Tillett
- W. Tillet, MBChB, PhD, Department of Life Sciences, Centre for Therapeutic Innovation, Royal National Hospital for Rheumatic Diseases, Bath, UK
| | - April W Armstrong
- A.W. Armstrong, MD, MPH, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Oliver FitzGerald
- S.R. Pennington, PhD, O. FitzGerald, MBBCh, MD, School of Medicine, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland;
| |
Collapse
|
4
|
Queiro R, Seoane-Mato D, Laiz A, Agirregoikoa EG, Montilla C, Park HS, Pinto-Tasende JA, Baute JJB, Ibáñez BJ, Toniolo E, Ramírez J, García AS. Characteristics associated with the perception of high-impact disease (PsAID ≥4) in patients with recent-onset psoriatic arthritis. Machine learning-based model. Semin Arthritis Rheum 2022; 57:152097. [PMID: 36113222 DOI: 10.1016/j.semarthrit.2022.152097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 08/31/2022] [Accepted: 09/05/2022] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To evaluate which patient and disease characteristics are associated with the perception of high-impact disease (PsAID ≥4) in recent-onset psoriatic arthritis. METHODS We performed a multicenter observational prospective study (2-year follow-up, regular annual visits). The study population comprised patients aged ≥18 years who fulfilled the CASPAR criteria and less than 2 years since the onset of symptoms. The dataset was generated using data for each patient at the 3 visits (baseline, first year, and second year of follow-up) matched with the PsAID values at each of the 3 visits. PsAID was categorized into two groups (<4 and ≥4). We trained a logistic regression model and random forest-type and XGBoost machine learning algorithms to analyze the association between the outcome measure and the variables selected in the bivariate analysis. A k-fold cross-validation with k = 5 was performed. RESULTS The sample comprised 158 patients. Of the patients who attended the clinic, 45.8% scored PsAID ≥4 at baseline; 27.1%, at the first follow-up visit, and in 23.0%, at the second follow-up visit. The variables associated with PsAID ≥4 were, in decreasing order of importance: HAQ, pain, educational level, and physical activity. Higher HAQ (logistic regression coefficient 10.394; IC95% 7.777,13.011), higher pain (5.668; 4.016, 7.320), lower educational level (-2.064; -3.515, -0.613) and high level of physical activity (1.221; 0.158, 2.283) were associated with a higher frequency of PsAID ≥4. The mean values of the measures of validity of the algorithms were all ≥85%. CONCLUSIONS Despite the higher weight given to pain when scoring PsAID, we observed a greater influence of physical function on disease impact.
Collapse
Affiliation(s)
- Rubén Queiro
- Rheumatology Service and the Principality of Asturias Institute for Health Research (ISPA), Faculty of Medicine, Universidad de Oviedo, Avenida de Roma s/n, Asturias, Oviedo 33011, Spain.
| | | | - Ana Laiz
- Rheumatology and Autoimmune Disease Department, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Carlos Montilla
- Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Hye-Sang Park
- Rheumatology and Autoimmune Disease Department, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jose A Pinto-Tasende
- Rheumatology Service-INIBIC, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | | | | | - Elide Toniolo
- Rheumatology Service, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain
| | - Julio Ramírez
- Arthritis Unit, Rheumatology Department, Hospital Clínic Barcelona, Barcelona, Spain
| | - Ana Serrano García
- Knowledge Engineering Institute, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
5
|
Maxwell LJ, Beaton DE, Boers M, D'Agostino MA, Conaghan PG, Grosskleg S, Shea BJ, Bingham Iii CO, Boonen A, Christensen R, Choy E, Doria AS, Hill CL, Hofstetter C, Kroon FP, Leung YY, Mackie S, Meara A, Touma Z, Tugwell P, Wells GA. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Semin Arthritis Rheum 2021; 51:1320-1330. [PMID: 34544617 DOI: 10.1016/j.semarthrit.2021.08.011] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 08/18/2021] [Accepted: 08/18/2021] [Indexed: 11/29/2022]
Abstract
INTRODUCTION OMERACT uses an evidence-based framework known as the 'OMERACT Filter Instrument Selection Algorithm' (OFISA) to guide decisions in the assessment of outcome measurement instruments for inclusion in a core outcome set for interventional and observational clinical trials. METHODS A group of OMERACT imaging and patient-centered outcome methodologists worked with imaging outcome groups to facilitate the selection of imaging outcome measurement instruments using the OFISA approach. The lessons learned from this work influenced the evolution to Filter 2.2 and necessitated changes to OMERACT's documentation and processes. RESULTS OMERACT has revised documentation and processes to incorporate the evolution of instrument selection to Filter 2.2. These revisions include creation of a template for detailed definitions of the target domain which is a necessary first step for instrument selection, modifications to the Summary of Measurement Properties (SOMP) table to account for sources of variability, and development of standardized reporting tables for each measurement property. CONCLUSIONS OMERACT Filter 2.2 represents additional modifications of the OMERACT guide for working groups in their rigorous assessment of measurement properties of instruments of various types, including imaging outcome measurement instruments. Enhanced reporting aims to increase the transparency of the evidence base leading to judgements for the endorsement of instruments in core outcome sets.
Collapse
Affiliation(s)
- Lara J Maxwell
- Faculty of Medicine, University of Ottawa, Ottawa, Canada.
| | - Dorcas E Beaton
- Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
| | - Maarten Boers
- Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Maria Antonietta D'Agostino
- Università Cattolica del Sacro Cuore, Rome, Italy; Rheumatology UOC, IRCSS, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy; Inserm U1173, Infection et inflammation, Laboratory of Excellence INFLAMEX, Université Paris-Saclay UVSQ, Montigny-le-Bretonneux, France
| | - Philip G Conaghan
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, UK
| | | | - Beverley J Shea
- Ottawa Hospital Research Institute, Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Clifton O Bingham Iii
- Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States
| | - Annelies Boonen
- Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, The Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands
| | - Robin Christensen
- Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark
| | - Ernest Choy
- CREATE Centre and Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff, UK
| | - Andrea S Doria
- The Hospital for Sick Children, Medical Imaging Department, University of Toronto, Toronto, Canada
| | - Catherine L Hill
- Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia
| | | | - Féline Pb Kroon
- Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
| | - Ying Ying Leung
- Department of Rheumatology & Immunology, Singapore General Hospital; Duke-NUS Medical School, Singapore
| | - Sarah Mackie
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Alexa Meara
- Division of Rheumatology and Immunology, Ohio State University, Wexner Medical Centre, Columbus, Ohio, United States
| | - Zahi Touma
- Division of Rheumatology, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Peter Tugwell
- Division of Rheumatology, Department of Medicine, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - George A Wells
- Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada; Department of Medicine, University of Ottawa, Ottawa, Canada; Ottawa Hospital Research Institute, Ottawa, Canada
| |
Collapse
|